[go: up one dir, main page]

YU53502A - Blokada aksonalnog rasta posredstvom nogo receptora - Google Patents

Blokada aksonalnog rasta posredstvom nogo receptora

Info

Publication number
YU53502A
YU53502A YU53502A YUP53502A YU53502A YU 53502 A YU53502 A YU 53502A YU 53502 A YU53502 A YU 53502A YU P53502 A YUP53502 A YU P53502A YU 53502 A YU53502 A YU 53502A
Authority
YU
Yugoslavia
Prior art keywords
nogo
nogo receptor
disclosed
axonal growth
mediated blockade
Prior art date
Application number
YU53502A
Other languages
English (en)
Inventor
Stephen Strittmatter
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of YU53502A publication Critical patent/YU53502A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Opisani su Nogo receptorski proteini i biološki aktivni Nogo (ligand) fragmenti. Takodje su opisani kompozicije i postupci za modulaciju ekspresionisanja ili aktivnosti Nogo ili Nogo receptorskog proteina. Takodje su opisani peptidi koji blokiraju Nogo-posredovane inhibicije aksonalnog protezanja. Kompozicije i postupci prema pronalasku su korisni za tretiranje kranijalnih ili cerebralnih trauma, ozleda kičmene moždine, šloga ili demijelinišućeg obolenja.[Disclosed are Nogo receptor proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and Nogo receptor protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.
YU53502A 2000-01-12 2001-01-12 Blokada aksonalnog rasta posredstvom nogo receptora YU53502A (sh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17570700P 2000-01-12 2000-01-12
US20736600P 2000-05-26 2000-05-26
US23637800P 2000-09-29 2000-09-29

Publications (1)

Publication Number Publication Date
YU53502A true YU53502A (sh) 2005-11-28

Family

ID=27390581

Family Applications (1)

Application Number Title Priority Date Filing Date
YU53502A YU53502A (sh) 2000-01-12 2001-01-12 Blokada aksonalnog rasta posredstvom nogo receptora

Country Status (27)

Country Link
US (1) US20020012965A1 (sh)
EP (2) EP2163561A1 (sh)
JP (1) JP4763207B2 (sh)
KR (1) KR100828058B1 (sh)
CN (1) CN100354307C (sh)
AT (1) ATE466882T1 (sh)
AU (1) AU784349C (sh)
BG (1) BG106907A (sh)
BR (1) BR0107613A (sh)
CA (1) CA2397199C (sh)
CZ (1) CZ20022438A3 (sh)
DE (1) DE60142023D1 (sh)
EA (1) EA008480B1 (sh)
EE (1) EE200200386A (sh)
ES (1) ES2341842T3 (sh)
GE (1) GEP20063830B (sh)
HK (1) HK1051543A1 (sh)
HU (1) HUP0203863A3 (sh)
IL (2) IL150566A0 (sh)
IS (1) IS6455A (sh)
MX (1) MXPA02006885A (sh)
NO (1) NO20023387L (sh)
NZ (2) NZ520065A (sh)
PL (1) PL356887A1 (sh)
SK (1) SK9992002A3 (sh)
WO (1) WO2001051520A2 (sh)
YU (1) YU53502A (sh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723488B2 (en) 1998-03-27 2010-05-25 Genentech, Inc. Monoclonal antibodies to secreted and transmembrane polypeptides
US7371836B2 (en) 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GEP20063830B (en) * 2000-01-12 2006-05-25 Univ Yale Nogo Receptor-Mediated Blockade of Axonal Growth
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
WO2002029059A2 (en) 2000-10-06 2002-04-11 Yale University Nogo receptor homologs
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
GB0101312D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
AU2002331180A1 (en) * 2001-08-27 2003-03-10 Novartis Pharma Gmbh Nogo receptor homologues and their use
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
FR2841261B1 (fr) * 2002-06-25 2004-08-27 Univ Pasteur Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire
EP1534736B1 (en) * 2002-08-10 2010-06-02 Yale University Nogo receptor antagonists
KR20050062525A (ko) * 2002-08-10 2005-06-23 예일 유니버시티 Ｎｏｇｏ 수용체 길항제
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
KR20050092366A (ko) 2002-12-06 2005-09-21 싱가포르 제너럴 하스피털 피티이 엘티디. 펩티드, 이에 대한 항체, 및 중추 신경계 손상의 치료에있어서의 이의 용도
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
SI1606409T1 (sl) 2003-03-19 2011-01-31 Biogen Idec Inc Vezavni protein receptorja Nogo
AU2004227392A1 (en) 2003-04-04 2004-10-21 University Of Rochester Identification of novel nogo-receptors and methods related thereto
US20070065429A1 (en) * 2003-04-16 2007-03-22 Biogen Idec Ma Inc. Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
EP1633315A4 (en) * 2003-05-15 2010-09-08 Univ Leland Stanford Junior Novel immunomodulating peptide
EP1631237B1 (en) * 2003-05-16 2016-11-30 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
EP1695061A4 (en) * 2003-12-16 2008-02-20 Childrens Medical Center METHOD OF TREATING NEUROLOGICAL DISORDERS
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
CA2582581A1 (en) * 2004-10-01 2006-05-04 Yale University Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof
US20090137484A1 (en) * 2004-12-01 2009-05-28 National University Of Singapore Neuronal Network-Interacting Peptide
WO2007008732A2 (en) 2005-07-07 2007-01-18 Yale University Compositions and methods for suppressing axonal growth inhibition
CN101495509B (zh) 2005-07-08 2015-04-22 比奥根艾迪克Ma公司 Sp35抗体及其用途
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
WO2007089601A2 (en) 2006-01-27 2007-08-09 Biogen Idec Ma Inc. Nogo receptor antagonists
WO2007133746A2 (en) * 2006-05-15 2007-11-22 Biogen Idec Ma Inc. Use of nogo receptor-1 (ngr1) antagonists for promoting oligodendrocyte survival
US8642040B2 (en) 2006-07-24 2014-02-04 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists
WO2008064292A2 (en) * 2006-11-21 2008-05-29 Abbott Laboratories Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES
US20090285803A1 (en) * 2008-05-13 2009-11-19 Jasvinder Atwal ANTI-PirB ANTIBODIES
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
CN104935294B (zh) * 2014-03-20 2018-07-20 晶宏半导体股份有限公司 振荡器
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
CN105061560B (zh) * 2015-07-17 2018-10-09 暨南大学 一种Nogo-A受体结合肽及其衍生物与应用
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5466585A (en) 1986-04-15 1995-11-14 Ciba-Geigy Corporation Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
WO1990005191A1 (en) 1988-11-04 1990-05-17 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5723719A (en) 1991-08-08 1998-03-03 Health Research Inc. Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
CA2119443C (en) 1991-09-20 1999-11-02 James M. Roberts Human cyclin e
PT620849E (pt) 1992-01-07 2003-11-28 Elan Pharm Inc Modelos animais transgenicos para a doenca de alzheimer
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
US5731490A (en) 1992-09-29 1998-03-24 The Ontario Cancer Institute Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
AU5891394A (en) 1993-02-11 1994-08-29 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DK75393D0 (da) 1993-06-24 1993-06-24 Symbicom Ab Production of protein
DE69430207T2 (de) 1993-10-28 2002-09-19 Houston Advanced Research Center, Woodlands Mikrofabriziertes poröses durchflussgerät
WO1995024488A1 (en) 1994-03-09 1995-09-14 Abbott Laboratories Transgenic animals producing oligosaccharides and glycoconjugates
FR2718329B1 (fr) 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
US5908969A (en) 1994-05-13 1999-06-01 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5728915A (en) 1995-05-08 1998-03-17 Children's Hospital, Inc. Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
KR100386046B1 (ko) * 1997-12-03 2003-06-02 제넨테크, 인크. 폴리펩티드 및 이를 암호화하는 핵산
AU762055B2 (en) * 1998-03-10 2003-06-19 Genentech Inc. Novel polypeptides and nucleic acids encoding the same
NZ507435A (en) * 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
AU3134799A (en) 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
JP3659405B2 (ja) * 1998-04-23 2005-06-15 ジェネンテック・インコーポレーテッド Ｓｈ２ドメイン含有ペプチド
IL139219A0 (en) * 1998-04-24 2001-11-25 Genentech Inc Fizz proteins
AU761340B2 (en) * 1998-06-02 2003-06-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU4682999A (en) * 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
NZ511683A (en) * 1998-11-06 2004-06-25 Martin E Schwab Nucleotide and protein sequences of nogo genes and methods based thereon for treatment of diseases that result in damage to the central system
MXPA01005169A (es) * 1998-12-01 2002-07-02 Genentech Inc Promocion o inhibicion deangiogenesis y cardiovascularizacion.
MXPA01006330A (es) * 1998-12-22 2002-07-02 Genentech Inc Metodos y composiciones para inhibir el crecimiento de celulas neoplasticas.
AU2883600A (en) * 1999-03-08 2000-09-28 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2362427A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
AU3632600A (en) * 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
EP1268506A4 (en) * 1999-07-30 2004-07-28 Millennium Pharm Inc SECRET PROTEINS AND THEIR USE
GEP20063830B (en) * 2000-01-12 2006-05-25 Univ Yale Nogo Receptor-Mediated Blockade of Axonal Growth

Also Published As

Publication number Publication date
NZ541694A (en) 2006-08-31
HK1051543A1 (zh) 2003-08-08
NO20023387L (no) 2002-09-11
MXPA02006885A (es) 2004-04-05
AU784349B2 (en) 2006-03-16
EA008480B1 (ru) 2007-06-29
NO20023387D0 (no) 2002-07-12
IL150566A (en) 2008-03-20
PL356887A1 (en) 2004-07-12
HUP0203863A3 (en) 2008-03-28
CZ20022438A3 (cs) 2002-10-16
WO2001051520A3 (en) 2002-04-18
ES2341842T3 (es) 2010-06-29
EP2163561A1 (en) 2010-03-17
CA2397199A1 (en) 2001-07-19
DE60142023D1 (de) 2010-06-17
HUP0203863A2 (hu) 2003-03-28
WO2001051520A2 (en) 2001-07-19
EP1248803B1 (en) 2010-05-05
WO2001051520A9 (en) 2002-07-18
BR0107613A (pt) 2002-11-19
EP1248803A2 (en) 2002-10-16
GEP20063830B (en) 2006-05-25
KR100828058B1 (ko) 2008-05-09
CA2397199C (en) 2013-12-24
BG106907A (bg) 2003-05-30
US20020012965A1 (en) 2002-01-31
CN1404488A (zh) 2003-03-19
NZ520065A (en) 2006-02-24
CN100354307C (zh) 2007-12-12
JP2003519481A (ja) 2003-06-24
AU2940101A (en) 2001-07-24
SK9992002A3 (en) 2003-05-02
EA200200755A1 (ru) 2002-12-26
ATE466882T1 (de) 2010-05-15
AU784349C (en) 2006-09-28
IL150566A0 (en) 2003-02-12
IS6455A (is) 2002-07-03
KR20020097157A (ko) 2002-12-31
EE200200386A (et) 2003-12-15
JP4763207B2 (ja) 2011-08-31

Similar Documents

Publication Publication Date Title
YU53502A (sh) Blokada aksonalnog rasta posredstvom nogo receptora
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
AU1153902A (en) Nogo receptor homologs
DE60028970D1 (de) An her2 bindende peptidverbindungen
SG157951A1 (en) Cripto blocking antibodies and uses thereof
EP2332977A3 (en) ActRII receptor polypeptides
MXPA05004225A (es) Anticuerpos de neutralizacion contra gdf-8, y sus usos.
AU1922101A (en) Human fgf-21 gene and gene expression products
WO2002044320A3 (en) Human elongase genes and uses thereof
AU6721998A (en) Therapeutic use of the smr1 protein and active derivatives thereof
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
WO2003003988A3 (en) Peptides which modulate blood coagulation and methods of use thereof
WO2004067725A3 (en) Methods of identifying modulators of nmur2-mediated activity
WO2000042165A3 (en) Bone marrow-specific protein
WO1999046381A3 (en) Human fgf gene and gene expression products
WO2002062996A1 (fr) Nouveau peptide physiologiquement actif et utilisation de ce peptide
UA32302A (uk) Спосіб усунення післяопераційних деформацій м'яких тканин